Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 13/20 | 0.39 |
| ▸ | MMP1 | P03956 | 8/20 | 0.39 |
| ▸ | MMP3 | P08254 | 8/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8971232 | 0.77 | CSNK1E (0.58) | CSNK1ECTSKCTSLCTSBMMP2 | |
| SCHEMBL21268579 | 0.76 | CSNK1E (0.55) | CSNK1ECTSKCTSLCTSBMMP2 | |
| SCHEMBL21268584 | 0.76 | CSNK1E (0.55) | CSNK1ECTSKCTSLCTSBMMP2 | |
| SCHEMBL9232199 | 0.76 | CSNK1E (0.55) | CSNK1ECTSKCTSLCTSBMMP2 | |
| SCHEMBL21268585 | 0.76 | CSNK1E (0.55) | CSNK1ECTSKCTSLCTSBMMP2 | |
| SCHEMBL28382981 | 0.75 | CSNK1E (0.39) | CSNK1ECTSK | |
| SCHEMBL9233306 | 0.74 | CSNK1E (0.53) | CSNK1ECTSKCTSLCTSBMMP2 | |
| SCHEMBL18705410 | 0.74 | ALDH1A1 (0.43) | — | |
| SCHEMBL9556242 | 0.73 | CSNK1E (0.56) | CSNK1ECTSKCTSLCTSBMMP2 | |
| SCHEMBL28037454 | 0.73 | CSNK1E (0.53) | CSNK1ECTSKCTSLCTSBMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989602-B2 | having biological activity similar to PIM (acyl glycerol phosphatidylinositol manno-oligosacccharide) activity; asthma, allergic rhinitis, dermatitis, psoriasis, inflammatory bowel disease including Crohn's disease and ulcerative colitis, rheumatoid arthritis, multiple sclerosis, diabetes, systemic lupus | THE MALAGHAN INSTITUTE OF MEDICAL RESEARCH (NZ) | 2011-08-02 | — | — | US | disclosed |
| US-20080249037-A1 | Synthetic Molecules Having Immune Activity | UNIVERSITY OF OTAGO (NZ) | 2008-10-09 | — | — | US | disclosed |
| WO-2005049631-A1 | SYNTHETIC MOLECULES HAVING IMMUNE ACTIVITY | THE MALAGHAN INSTITUTE OF MEDICAL RESEARCH (NZ) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249037-A1 | Synthetic Molecules Having Immune Activity | ALG1, PAG1, SIGLEC7 | CSNK1E 4032/4885CTSK 1148/4885CTSL 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.